immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable microarray: suitable western blot: 1:1,000 using a fresh total bovine brain extract or an enriched microtubule protein preparation
Monoclonal Anti- τ (TAU) (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. τ (TAU) proteins are a part of microtubule associated proteins (MAPs). They are densely found in neurons and in trace amounts in non-neuronal cells. In brain six isoforms of τ (TAU) proteins are present.
The antibody reacts exclusively with the chemically heterogeneous τ in both the phosphorylated and non-phosphorylated form. The antibody does not react with other MAPs or with tubulin. In immunohistochemical staining, it localizes τ along microtubules in axons, somata, dendrites and astrocytes, and on ribosomes. The antibody may be used for staining of τ in Alzheimer neurofibrillary tangles in sections of human brain tissue.
The best known microtubule associated proteins (MAPs) which copurify with microtubules are MAP2 and Tau. These two proteins are heat stable and stimulate formation of the microtubule polymer from purified tubulin subunits. Tau is chemically heterogenous, however, limited protolysis has demonstrated that the different eletrophoretic species are closely related. Tau is immunologically distinct from the other MAPs, namely MAP1, MAP2 and MAP5. Localization studies have demonstrated that Tau is intimately associated with the filamentous structures which compose the neurofibrillary tangles as found in an Alzheimer′s disease brain.
면역원
bovine microtubule-associated proteins (MAPs)
애플리케이션
Monoclonal Anti-τ (Tau) antibody has been used:
in immunohistology
in immunoblotting
in dot blot
in immunohistochemistry
Mouse monoclonal clone TAU-2 anti-Tau antibody maybe used to study microtubule associated proteins (MAP) expression and cytological localization in various tissue and cell lines, under different developmental and environmental circumstances.
생화학적/생리학적 작용
Monoclonal Anti- τ (TAU) is phosphatase independent; it will bind Tau proteins in either their phosphorylated or non-phosphorylated forms. It localizes Tau proteins along microtubules in axons, somata, dendrites, astrocytes and on ribosomes (polysomes). The best-known microtubule associated proteins (MAPs) which copurify with microtubules are MAP2 and Tau. These two proteins are heat stable and stimulate formation of the microtubule polymer from purified tubulin subunits. Tau is immunologically distinct from the other MAPs. Tau is intimately associated with the filamentous structures which compose the neurofibrillary tangles as found in an Alzheimer′s disease brain.
면책조항
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The roles of activated glia and of glial cytokines in the pathogenesis of Alzheimer's disease are reviewed. Interleukin-1 (IL-1), a microglia-derived acute phase cytokine, activates astrocytes and induces expression of the astrocyte-derived cytokine, S100 beta, which stimulates neurite growth (and
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy.
Sharon Kemp et al.
Movement disorders : official journal of the Movement Disorder Society, 28(13), 1804-1806 (2013-10-15)
Journal of molecular neuroscience : MN, 45(1), 32-41 (2011-02-23)
Lesions containing aggregated and hyperphosphorylated tau protein are characteristic of neurodegenerative tauopathies. We have developed a cellular model of pathological tau deposition and clearance by overexpressing wild type human tau in HEK293 cells. When proteasome activity is inhibited, HEK293/tau cells
Brain : a journal of neurology, 128(Pt 10), 2272-2280 (2005-07-15)
Changes in motor cortical activation are associated with the major symptoms observed in both Parkinson's disease and progressive supranuclear palsy (PSP). While research has concentrated on basal ganglia abnormalities as central to these cortical changes, several studies in both disorders